Anatara Lifesciences Ltd (ASX:ANR) CEO Steve Lydeamore was recently interviewed by Stockhead, for its “90 Seconds With” interview series, providing an overview of the Company’s gastrointestinal health products, as well as the upcoming newsflow for the next 12months.
1. Can you provide our investor audience with an overview of Anatara Lifesciences?
2. What can investors expect to see from Anatara Lifesciences over the next 6-12 months?
Anatara Lifesciences (ASX:ANR) is developing and commercialising a range of gastrointestinal health products focused on animal and human health. The company’s lead product, Detach, is a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour), which affects livestock. Anatara is also developing Gastrointestinal ReProgramming (GaRP), a microbiome-targeted dietary supplement. The product is designed to address the primary underlying factors associated with gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).